113 related articles for article (PubMed ID: 10412269)
1. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
3. p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study.
Stefanou DG; Nonni AV; Agnantis NJ; Athanassiadou SE; Briassoulis E; Pavlidis N
Anticancer Res; 1998; 18(6B):4673-81. PubMed ID: 9891539
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
[TBL] [Abstract][Full Text] [Related]
5. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
6. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970
[TBL] [Abstract][Full Text] [Related]
8. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
9. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
10. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities.
Würl P; Meye A; Schmidt H; Lautenschläger C; Kalthoff H; Rath FW; Taubert H
Oncogene; 1998 Mar; 16(9):1183-5. PubMed ID: 9528860
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas.
Würl P; Meye A; Berger D; Bache M; Lautenschläger C; Schmidt H; Kalthoff H; Rath FW; Taubert H
Diagn Mol Pathol; 1997 Oct; 6(5):249-54. PubMed ID: 9458382
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours.
Kindblom LG; Ahldén M; Meis-Kindblom JM; Stenman G
Virchows Arch; 1995; 427(1):19-26. PubMed ID: 7551341
[TBL] [Abstract][Full Text] [Related]
15. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
17. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
[TBL] [Abstract][Full Text] [Related]
18. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
Ito E; Saito K; Takizawa T; Koike M
J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
[TBL] [Abstract][Full Text] [Related]
19. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery.
Bode-Lesniewska B; Zhao J; Speel EJ; Biraima AM; Turina M; Komminoth P; Heitz PU
Virchows Arch; 2001 Jan; 438(1):57-65. PubMed ID: 11213836
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
